Background -As women with cystic fibrosis are living longer, pregnancy is becoming increasingly common. The combined experience of pregnancies in women with cystic fibrosis from adult centres in the Midlands and North of England has been examined. Those involved in caring for adults with cystic fibrosis are encountering increasing numbers of patients seeking guidance about the advisability of pregnancy. What counselling should they offer? A recent review article6 commented that prepregnancy lung function and body weight might be useful indicators of outcome for both mother and child. We have combined the experience of our own and neighbouring cystic fibrosis centres in the UK to provide guidelines for the clinical care and counselling of these patients.
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Background -As women with cystic fibrosis are living longer, pregnancy is becoming increasingly common. The combined experience of pregnancies in women with cystic fibrosis from adult centres in the Midlands and North of England has been examined. Methods -A retrospective study ofthe case notes of 22 pregnancies in 20 patients with cystic fibrosis examined changes in lung function, body weight, and microbiological status during the course ofpregnancy. Duration of pregnancy, birth weight, and maternal survival were amongst other variables studied. The relation between values before pregnancy and important outcome measures were examined. Results -Eighteen of 22 pregnancies were completed producing healthy, non-cystic fibrosis infants (12 female Patients with cystic fibrosis are living longer. ' As the numbers surviving to adulthood increase, pregnancy in young women with cystic fibrosis, previously a rare event, is now becoming increasingly common. The first report of a successful pregnancy in a patient with cystic fibrosis appeared in 19602; by 1976 a cumulative total of 129 pregnancies in 100 women was identified in the USA and Canada3 and in 1990 alone the Cystic Fibrosis Foundation in the USA was notified of 111 pregnancies occurring in the national network of cystic fibrosis care centres.4 Increasing numbers of pregnancies have also been noted in Europe.5
Those involved in caring for adults with cystic fibrosis are encountering increasing numbers of patients seeking guidance about the advisability of pregnancy. What counselling should they offer? A recent review article6 commented that prepregnancy lung function and body weight might be useful indicators of outcome for both mother and child. We have combined the experience of our own and neighbouring cystic fibrosis centres in the UK to provide guidelines for the clinical care and counselling of these patients.
Methods
The case notes of 22 pregnancies in 20 women with cystic fibrosis attending specialist centres in the Midlands and North of England were reviewed. These centres provide full or shared care for about 400 Four of the pregnancies were incomplete. Two patients underwent therapeutic abortions at seven and 10 weeks for psychosocial reasons, although one of these subsequently had a successful second pregnancy. A third patient underwent abortion at 18 weeks due to the discovery of fetal anomalies (diaphragmatic hernia and pulmonary hypoplasia) on routine antenatal ultrasound examination. This patient had received 63 g ciprofloxacin and 100 g flucloxacillin orally, with 170 g azlocillin and 3-7 g gentamicin intravenously during the first trimester of pregnancy. A literature search (Medline) failed to show any reported association between these drugs and the anomalies found which have a naturally occurring frequency of 1:2000 births in a normal population.9 The fourth patient spontaneously aborted in the tenth week of pregnancy.
COMPLETED PREGNANCIES
The remaining 18 pregnancies in 17 patients produced healthy, non-cystic fibrosis children of whom 12 (66%) were female. The mean (SD) duration ofpregnancy was 37 (2 9) weeks (range 31-40) with six infants being preterm (gestation <37 weeks). Seven mothers had unassisted vaginal deliveries, four required forceps, and one ventouse assistance. The remaining six mothers required caesarean sections, all performed preterm because of deteriorating maternal pulmonary function. Birth weights ranged from 1-5 kg to 4-1 (0 7) kg with a mean value of 2-9 kg. Two infants were light for dates, being below the 10% percentile for gestational age at birth. Apgar scores at one and five minutes were available for 13 of the pregnancies with mean values of 8 at one minute and 10 at five minutes. The lowest Apgar score was 5 at one minute (to a mother with moderate to severe prepregnancy lung disease, %FEV, 49%) in one infant who improved to a score of 10 at five minutes. Two babies required a degree of intensive support in the neonatal period; one infant spent 12 hours in an incubator whilst the second required assisted ventilation. Both survived and subsequently did well. None of the babies had congenital anomalies.
EFFECT OF PREGNANCY ON MATERNAL PARAMETERS
Changes in lung function during and after pregnancy for all patients are shown in figs 1 and 2. The general pattern seen was that of a loss in lung function during pregnancy which was largely regained following pregnancy. The group as a whole lost 13% of FEV, and 11% of FVC during pregnancy; one year after pregnancy the loss in FEV, was only 5% and in FVC was 2%. Individual patterns were quite variable, however, and some patients gained lung function during pregnancy whilst others suffered an increased rate of loss of lung function after pregnancy compared with that seen during pregnancy. Changes in body weight during and after pregnancy are shown in fig 3. The pattern for the group as a whole was one of a weight gain of 11% (an absolute gain of 5-7 kg) during pregnancy which was subsequently lost after pregnancy with no overall weight change one year after delivery. Again, individual patterns were quite variable; two patients lost weight during pregnancy and seven had lost weight up to one year after pregnancy compared with prepregnancy values.
Microbiological status remained unchanged for all mothers during pregnancy. No patients acquired either intermittent (single culture) or chronic (more than three cultures in six months) Pseudomonas colonisation over the period of assessment. Significant complications arising during pregnancy included a third trimester tension pneumothorax in one patient and a rib fracture and pre-eclampsia in a second, both of whom had moderate to severe prepregnancy pulmonary disease (%FEV, 39% and 50%) and have subsequently died.
Overall there have been four maternal deaths amongst the 17 patients who had successful pregnancies, all in mothers with moderate to severe lung disease at the onset of pregnancy (%FEV, values of 39%, 49%, 50%, and 50%).
These deaths occurred at 0 5, 1 8, 2-4, and 3-2 years after delivery. All of these mothers lost more than 10% of FEV, during pregnancy which three of them failed to regain up to one year (six months in the case of one patient) after delivery. All the mothers with mild lung disease (%FEV, >60%) and two with severe lung disease (%FEV, 28% and 32%) at the onset of pregnancy survive with children ranging from 0-9 to 12 years of age, although one of these mothers who lost 56% of her FEV, during pregnancy was listed for heart-lung transplantation three months after delivery. Patients with cystic fibrosis frequently require antimicrobial therapy during pregnancy as was the case with most of our patients. Most clinicians try to avoid giving antimicrobial drugs during the first trimester and certain antibiotics such as tetracyclines and ciprofloxacin should be avoided throughout pregnancy. Aminoglycosides, often the mainstay of antipseudomonal chemotherapy in cystic fibrosis, are considered safe as long as serum levels are closely monitored'2 and can be used by both intravenous and inhaled routes. Antipseudomonal penicillins and cephalosporins may also be used by both routes. Maintenance flucloxacillin, inhaled antibiotics, pancreatic enzymes (when appropriate), and vitamin supplements should be continued throughout pregnancy.
A high proportion of our patients (nine of 20, 45%) admitted to smoking at the time of becoming pregnant despite prior advice to the contrary. The effects of smoking on the unborn fetus may be used as an additional factor in attempting to persuade these patients to give up.
Antenatal screening for cystic fibrosis via chorionic villus sampling or amniocentesis may be appropriate if the partner of a mother with cystic fibrosis has been shown to carry a common cystic fibrosis mutation. This was not the case with any of our mothers whose partners were tested. The risk of an affected infant for a mother with cystic fibrosis whose partner does not carry a common cystic fibrosis gene (responsible for about 85% ofthe cystic fibrosis gene pool) is about 1:160; all offspring, however, will be obligate heterozygotes.
Various publications have suggested a number ofprepregnancy parameters that might usefully be considered in assessing the likely outcome of a pregnancy in the individual with cystic fibrosis. Most have included some measure of lung function and nutritional status; others have also included radiographic features and clinical scoring systems." Our own study suggests that, of the parameters we have assessed, the %FEV1 most influences important outcome measures of pregnancy in patients with cystic fibrosis. Mothers with a prepregnancy %FEV, of >60% all did well, whilst two thirds ofthose with a prepregnancy %FEV1 of <60% died within 3-2 years of delivery. This mortality may in part reflect the natural progression of lung disease, although pregnancy itself caused a significant added decline since, in three of these four patients, the loss of %FEV1 after pregnancy was much greater than for the group as a whole (37% versus 5%). Although most studies report only perinatal maternal mortality, the issue of maternal death within the preschool lifetime of the infant is clearly an important one. Similarly, mothers with moderate to severe prepregnancy pulmonary disease all had preterm infants (five of the six by caesarean section) compared with only one preterm infant (also by caesarian section) in the group of mothers with mild disease.
In summary, our experience is in keeping with that ofothers. 2 No mothers or infants died in the immediate perinatal period in contrast to experiences in the 1960s. Mothers with mild prepregnancy pulmonary disease tolerated pregnancy well. Those with moderate to severe disease are faced with an increased risk of pulmonary deterioration and the production of premature infants, although all infants of our mothers with moderate to severe disease have survived and remain healthy.
How should we advise our patients with cystic fibrosis who are considering pregnancy and motherhood? Clearly a number of issues need to be discussed. Even patients with excellent lung function may find that caring for a new baby considerably reduces the amount of time they have for their own treatment and physiotherapy. For those with more severe disease, their own health and the care of their baby may be compromised by progression of lung disease and the possibility that the mother may die before the child is very old also needs to be considered. Balanced against this is the generally good experience ofmothers with good prepregnancy lung function. Quite where the emphasis should lie for each individual depends upon several factors, but our study underlines the usefulness of measurements of prepregnancy lung function in predicting the likely outcome for our patients.
